The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 15.25 AMA PRA Category 1 Credit(s)™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by May 1, 2023. Certificates will only be issued to those who complete the survey. To access the Request for Credit Survey click here. It will also be emailed to you after the activity. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
There have been recent unprecedented improvements in immunotherapies, opening the avenue to develop combinatorial targeted and immunotreatment. The conference will seek to educate physicians on the landscape of emerging cancer treatments and the use of novel profiling methods as a means for optimizing treatment selection. Physicians participating in this CME activity will gain knowledge on the standard use of targeted therapies and immunotherapies for patients with cancer. Presentations will address various aspects of how DNA damage impacts the immune response covering the use of targeted and personalized immunotherapy treatments and the development of methods to profile patients for treatment selection and to identify mechanisms of drug resistance, including multi-omics approaches and AI development.
The integrity of DNA molecules is vital for proper cellular function, yet it is under constant assault from environmental and metabolic DNA damaging agents. Failure to maintain faithful DNA replication and as such genome stability and integrity leads to DNA lesions and mutations that are a driving factor in tumour initiation and progression. Cancer development is further modulated by the immune response.
Recent research has uncovered a role for DNA repair mechanisms beyond tumorigenesis. It is now known that DNA repair is at the core of regulating the balance between tumour progression and immune response, and as such can predict the efficacy of immunotherapy.
This conference builds upon recent insights gained into mechanisms of immune cell recognition and killing of tumor cells and insights into mechanisms of DNA repair that impact tumor development and tumor responses to targeted, systemic, and immunologic-based therapies. The important gap being filled is the intersection of these two fields (cancer immunobiology and DNA damage signaling and repair) and how to use that intersection to improve cancer prevention or treatment. Of particular focus is how altered DNA repair pathways in tumor cells affects the ability of the immune system to recognize and kill tumor cells and novel therapeutic approaches that can be used to enhance the efficacy of immune-modulation in controlling or preventing cancer. Presentations at this conference will help interpret recent research for the benefit of physicians and scientists who wish to use it to develop new therapeutic approaches to cancer prevention or more effectively treating patients with cancer.
After participating in this CME activity, physicians should be able to:
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with ineligible companies whose primary business is producing , marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.
Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants which will be disclosed at the activity.
Questions about CME?
Please contact the Office of CME at (215) 440-9300 or firstname.lastname@example.org.
This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.